Your patient has been taking fluoxetine (Prozac) for 2 years and reports feeling cured of depression. You learn that the patient is sleeping well, participates in his usual activities, and feels upbeat and energetic most of the time. His weight has returned to normal. He reports last having symptoms of depression at least 9 months ago. What will you tell this patient?

Antipsychotic medications, including low-potency agents, require adequate time to demonstrate full therapeutic effects on psychotic symptoms. Antipsychotics work primarily by modulating dopamine pathways, but clinical improvement, especially in hallucinations, delusions, and thought disturbances, may take several weeks. Early treatment response is often gradual, with some symptoms improving before others. Evaluation of effectiveness should consider duration of therapy, adherence, and expected pharmacologic onset.

Rationale:
A. It is too early to see a full therapeutic response because antipsychotic medications typically require 2–6 weeks or longer to show significant improvement in psychotic symptoms. Early partial response may be subtle, especially in negative symptoms or cognitive changes. At only 2 weeks, continued therapeutic effect is still expected as dopamine receptor adaptation continues over time.

B. Refractory illness refers to treatment-resistant psychosis, which is diagnosed only after adequate trials of multiple antipsychotics at therapeutic doses and durations. A 2-week trial is insufficient to determine treatment failure. Labeling the illness as refractory at this stage would be premature and clinically inaccurate.

C. Nonadherence cannot be assumed without evidence such as missed doses, inconsistent serum levels, or patient report. While noncompliance is a common issue in psychiatric treatment, the question provides no indication of medication refusal or poor adherence. Clinical evaluation should first consider expected drug response timelines.

D. Increasing to a stronger medication is not indicated at this stage because therapeutic response has not yet had adequate time to develop. Premature medication escalation may increase side effects without improving outcomes. Standard practice is to allow sufficient trial duration before changing antipsychotic potency or class.

Medication overuse headache (MOH) is a chronic daily headache that develops from the frequent use of acute headache medications. It occurs when repeated exposure to analgesics or antimigraine drugs leads to rebound headaches due to central sensitization and altered pain pathways. MOH is most commonly seen in patients with underlying migraine or tension-type headaches who rely heavily on abortive therapies. Recognizing causative medications is essential to prevent and manage this condition.

Rationale:
A. Triptans are commonly associated with medication overuse headache when used frequently for acute migraine relief. Drugs such as Sumatriptan can lead to rebound headaches due to repeated serotonin receptor stimulation and withdrawal effects. Regular overuse alters pain modulation pathways, increasing headache frequency and severity.

B. Opioids are strongly linked to the development of MOH due to their central nervous system effects and potential for dependence. Frequent use leads to increased pain sensitivity (opioid-induced hyperalgesia) and rebound headaches. Their use for headache management is generally discouraged due to this high risk.

C. Dihydroergotamine, an ergot derivative used for acute migraine treatment, can cause MOH when used excessively. It induces vasoconstriction and affects serotonin receptors, and repeated use can disrupt normal vascular and neurologic regulation. This contributes to chronic headache patterns.

D. Aspirin, a commonly used analgesic, can contribute to MOH when taken frequently for headache relief. Chronic use leads to rebound headaches as the body adapts to continuous inhibition of prostaglandin synthesis. This is especially true when used daily or in combination with other analgesics.

E. Caffeine, often included in combination headache medications, is a known contributor to MOH. Regular intake can lead to dependence and withdrawal headaches when levels drop. Its vasoconstrictive and stimulant effects can perpetuate a cycle of headache recurrence with frequent use.

F. Ergotamine is another ergot derivative associated with MOH when overused. Like dihydroergotamine, it affects vascular tone and serotonin pathways. Chronic use leads to rebound headaches and potential toxicity, making careful monitoring essential.